U.S. Markets closed

Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
180.11+3.17 (+1.79%)
At close: 04:00PM EDT
179.41 -0.70 (-0.39%)
After hours: 07:27PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close176.94
Bid174.82 x 1000
Ask188.78 x 1000
Day's Range174.52 - 180.49
52 Week Range105.43 - 192.79
Avg. Volume1,387,450
Market Cap32.934B
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-1.84
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est159.88

    Biotech Stocks Finally Rose in June. What Does It Mean?

    The (ticker: XBI), which tracks small- and mid-cap biotech stocks, fell 33.7% in the first half of the year, which ended on Thursday. The (IBB), which tracks larger biotech names, fell 22.8%. In a note out early Friday, analysts with Cowen biotechnology team noted that June represented the XBI’s first positive month since last August.

  • Zacks

    Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy

    Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Benzinga

    SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

    SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive. Related: Merck Shows Takeover Interest In Seagen: WSJ. According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in